Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 45: 478-485, 1999;
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dahler-Eriksen, B. S.
Right arrow Articles by Brandslund, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dahler-Eriksen, B. S.
Right arrow Articles by Brandslund, I.
Related Collections
Right arrow Clinical Immunology
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1999;45:478-485.)
© 1999 American Association for Clinical Chemistry, Inc.


Articles

Near-Patient Test for C-Reactive Protein in General Practice: Assessment of Clinical, Organizational, and Economic Outcomes

Bjarne Steen Dahler-Eriksen1,2,a, Torsten Lauritzen2, Jens Flensted Lassen2, Erik D. Lund1 and Ivan Brandslund1

1 Department of Clinical Chemistry, Vejle County Central Hospital, DK-7100 Vejle, Denmark.

2 Department of General Practice, University of Aarhus, DK-8000 Aarhus, Denmark.
a Address correspondence to this author at: Department of Clinical Chemistry, Vejle County Central Hospital, DK-7100 Vejle, Denmark. Fax 45 75 82 18 14.


   Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
Background: The benefits of near-patient, point-of-care tests have not been fully examined. We have assessed the clinical, organizational, and economic outcomes of implementing a near-patient test for C-reactive protein (CRP) in general practice.

Methods: In a randomized crossover trial during intervention periods, general practitioners (GPs) were allowed to measure CRP within 3 min, using NycoCard® CRP. During control periods, they had to mail blood samples for CRP measurements to the hospital laboratory and received test results 24–48 h later. Twenty-nine general practice clinics participated (64 GPs), and 1853 patients were included in the study. Results were evaluated at both the level of participating GPs and the level of included patients.

Results: For participating GPs, the overall use of erythrocyte sedimentation rates (ESRs) decreased by 8% (95% confidence interval, 1–14%) during intervention periods, and the number of blood samples mailed to the hospital laboratory decreased by 6% (1–10%). No reduction in the prescription of antibiotics was seen. The proportion of study patients having a follow-up telephone consultation was reduced from 63% to 53% (P = 0.0001), and patients with CRP concentrations >50 mg/L had their antibiotic treatments started earlier when CRP was measured in general practices (P = 0.0161).

Conclusion: The implementation of the near-patient CRP test was cost-effective mainly on the basis of a reduction in the use of services from the hospital laboratory by GPs. If the implementation is followed by education and clinical guidelines, opportunities exist for additional reduction in the use of ESR and for a more appropriate use of antibiotics.© 1999 American Association for Clinical Chemistry


   Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
C-reactive protein (CRP)1 is an acute phase protein widely used for the diagnosis and follow-up of infectious diseases in hospitals (1)(2)(3)(4). In general practice, CRP is found valuable in the diagnosis of bacterial diseases and in the differentiation between bacterial and viral infections (5)(6)(7). Often the diagnostic value of CRP is found superior to that of the erythrocyte sedimentation rate (ESR) (7)(8)(9) and superior or equal to that of the white blood cell count (WBC) (5)(8)(9).

In Denmark, general practitioners (GPs) request CRP by mailing blood samples to hospital laboratories, and the test is ordered for 34% of all patients having a blood sample mailed (10). Several near-patient tests for CRP measurements are available commercially. We have evaluated one of these tests (NycoCard® CRP) and found it reliable and robust for the use in general practice (11). In questionnaire surveys, it has been proposed that knowing the CRP value while having the patient in the office may give GPs better guidance for the prescription of antibiotics than ESR (12)(13).

Implementation of near-patient tests in general practice should be based on an outcomes assessment with documentation for the clinical outcomes (14). However, outcomes for the organization and economic outcomes are important features and should be included in an assessment (15). Therefore, results of a technology assessment should be available before the decision to introduce the test is made (16)(17).

The aim of this study was to assess the clinical, organizational, and economic consequences of introducing a near-patient test for CRP measurements in general practice, with special focus on the clinical use of the test, the additional use of ESR, prescription of antibiotics, and utilization of the hospital laboratory service.


   Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
The catchment area of the hospital laboratory at the Vejle County Central Hospital (Vejle Hospital) covers 136 000 inhabitants and 41 general practice clinics (90 GPs), of which all were invited to participate in this study; 29 clinics (70.1%) accepted [a total of 64 GPs (71.1%)].

intervention
The clinics were randomized into two groups. One group was given access to a near-patient test for CRP (NycoCard CRP Whole Blood; Nycomed Pharma) in the office (intervention), whereas the other group had to order CRP as usual, mailing a blood sample to the laboratory (control). After a period of 3 months, the two groups interchanged their status (crossover). The first period of intervention and control was 3 months (April–June 1996), and the second period was 4 months (July–October 1996). All clinics received an introductory visit with a demonstration by the manufacturer before their intervention period. No clinical guidelines for the use of CRP were distributed to the clinics.

inclusion of patients
The GPs filled out a registration card for each patient when a CRP was measured in the office or requested at the laboratory. The date for the consultation, the tentative diagnosis, and the CRP value were registered together with the patient's personal registration number.

the danish health service system and the laboratory information system
All inhabitants in Denmark have a personal registration number, and it is therefore possible to collect information about any person from independent registries (18). Of the population, 97% are registered at their GPs (19). The GPs receive a basic fee from the Danish Health Service System for every registered person and an extra fee for several specified services such as consultations, laboratory tests, and mailing of patient samples to laboratories. These services, as well as prescription of drugs, are registered by the Health Service System and can, on application, be used for scientific purpose (18). Partnership general practices have the same registration number, which allows no differentiation between individual GPs in a clinic. In the county of Vejle, all test results from hospital laboratories are stored in a Laboratory Information System for 5 years for all 340 000 inhabitants.

outcome measurements at the clinic level
From the regional office of the Health Service System, we received data on the following: (a) the number of patients registered at each clinic; (b) the date of consultation and personal registration number for all patients receiving one of the following services: ESR, WBC, antigen test for group A streptococci, bacterial culture, urine susceptibility test, and microscopy of urine and bacteria; and (c) all antibiotics dispensed in 1996.

From the Laboratory Information System at Vejle Hospital, we received data for all blood tests requested in 1996.

outcome measurements at the patient level
Some outcome measurements were available only at the patient level, including the number of follow-up consultations.

statistical analyses
Results were calculated at the patient level by use of {chi}2 tests, unpaired t-tests, and Mann–Whitney tests. At the clinic level crossover t-test statistics were used (20). The inclusion rates were assessed for each clinic in intervention and control periods. If a clinic had an inclusion rate <75% in either period, all patients from that clinic were excluded from the study. The clinic itself was not excluded because all outcome measurements at the clinic level were based on data from the Health Service System and the Laboratory Information System, and therefore were independent of the registration of included patients.

ethics
The study was approved by the Danish Data Protection Agency, and the local scientific ethics committee was informed about the study.


   Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
It was possible to evaluate data in this study, both at the level of included patients and at the overall level of participating general practice clinics. Results at the level of included patients were suitable to describe the categories of patients having their CRP measured and to evaluate prescription of antibiotics at patient level. Results at the level of included patients are presented in Tables 1–4 . Results at the level of general practice clinics were suitable for organizational and economic evaluation, and these results are presented in Tables 5 and 6 .


View this table:
[in this window]
[in a new window]
 
Table 1. Reasons registered by GPs for ordering a CRP measurement and patients' tentative diagnoses.


View this table:
[in this window]
[in a new window]
 
Table 2. Additional tests carried out in general practice and numbers of consultations and services from the hospital laboratory at the level of included patients.


View this table:
[in this window]
[in a new window]
 
Table 3. Prescription of antibiotics at different CRP values during intervention and control periods.1


View this table:
[in this window]
[in a new window]
 
Table 4. Patients' delay for collecting their antibiotics at a pharmacy after having CRP measured.


View this table:
[in this window]
[in a new window]
 
Table 5. Changes in use of additional tests, use of hospital laboratory services, and prescription of antibiotics by GPs.1


View this table:
[in this window]
[in a new window]
 
Table 6. Cost-effectiveness of implementing CRP as a near-patient test in general practice in the county of Vejle, Denmark,1 based on effects of intervention reported in Table 5Up .

results at the level of included patients
During the study period, 2915 patients were registered at their GPs: 1560 (53.3%) during intervention periods and 1355 (46.5%) during control periods. During the intervention periods, all 29 clinics had an inclusion rate near 100%; however, during the control periods, 13 clinics had an inclusion rate <75% (range, 6–67%). All 1041 patients registered by these clinics were excluded. Of the remaining 1874 patients, 21 were excluded because of incomplete registration of personal registration numbers, leaving 919 patients included in the intervention periods and 934 patients included in the control periods.

Sex and age characteristics.
The mean age of the included patients was 53.7 years [95% confidence interval (CI), 52.8–54.6%], and 60.2% (95% CI, 58.0–62.4%) of the patients were women.

Reasons for measuring CRP and disease characteristics.
The disease characteristics for the included patients are given in Table 1Up . During intervention periods, the use of CRP was significantly higher for "diagnosis of new diseases" and "infectious diseases". For patients with sinusitis, the use of CRP during intervention periods was threefold higher than during the control periods, whereas changes for other specified infectious diseases are insignificant. There was a significant decrease in follow-up testing during intervention periods. The decrease in follow-up testing was seen mainly in the group of patients without infections, with a decrease from 18.1% during control periods to 12.8% during intervention periods (P = 0.002). Follow-up testing for patients with infectious diseases decreased from 8.1% to 5.9% (P = 0.07). The use of CRP for chronic inflammatory diseases and other diseases was equally distributed in the periods.

Additional tests, consultations, and laboratory services.
The number of additional tests and consultations together with the use of laboratory services is given in Table 2Up . The use of ESR was significantly (11%) lower during intervention periods, and the decrease was significant both for patients with CRP values within the health-related reference interval and for patients with high values. For patients with CRP values <=10 mg/L, the decrease was 9.1% (P = 0.002); for patients with CRP values between 10 and 25 mg/L, the decrease was 12% (P = 0.043); and for patients with CRP values >=25 mg/L, the decrease was 12.6% (P = 0.014). The use of other supplementary tests remained unchanged. The use of follow-up telephone consultations was also lower during intervention periods, whereas the number of daytime and out-of-hours consultations was unchanged. During control periods, 140 patients (15.0%) had a blood sample forwarded for a CRP measurement only, but the total number of blood samples forwarded to the laboratory declined significantly, from 100% to 60.2%, during intervention periods, which is a reduction of nearly 40%. This reflects a reduction in the number of patient samples forwarded containing a request for other analyses in addition to a CRP measurement. The mean number of requests for additional laboratory tests for each forwarded blood sample was 4.8 tests in intervention periods and 5.5 tests in control periods (i.e., CRP exclusive). In both periods, creatinine, alanine aminotransferase, alkaline phosphatase, WBC, and potassium were the most frequently requested additional tests.

Prescription of antibiotics.
In Table 3Up , the prescription of antibiotics is compared for different CRP concentrations. Patients with infection as the tentative diagnosis and with unspecific diagnoses such as fever, cough, or dyspnea are included. Patients in a follow-up course and with appendicitis were excluded. Antibiotics were prescribed for approximately one-third of all patients with a sign of infection during both intervention and control periods. During both periods, the frequency of prescription increases with an increased magnitude of CRP values (test for trend; P <0.0001). During both periods, 20% of the patients with a health-related CRP value received an antibiotic prescription. These patients had the same distribution of infectious diagnoses as described in Table 1Up .

There were no differences between types of antibiotics prescribed during intervention and control periods. In both periods, narrow spectrum penicillin was the most frequently used antibiotic (45%), followed by macrolides (22%), broad spectrum penicillins (20%), quinolones (8%), and sulfa drugs (3%).

Patient delays for collecting antibiotics.
By comparing the date that CRP was measured in each patient with the date that the prescribed antibiotic was dispensed by a pharmacy, a delay for collecting antibiotics can be estimated for each patient (Table 4Up ). Patients with a CRP value >50 mg/L had a significantly lower delay in collecting their antibiotics during intervention periods than during control periods.

results at the level of general practice clinics
Intervention effects.
Quick access to CRP measurements led to a reduction of the overall use of ESR by GPs of 8%, whereas their use of other tests was unchanged. The number of CRP tests forwarded to the laboratory was reduced by 65%, and the overall number of blood samples forwarded by GPs was reduced by 6% (Table 5Up ).

Economic evaluation.
The cost-effectiveness for CRP as a near-patient test was calculated (Table 6Up ) on the basis of intervention effects (Table 5Up ). Implementation of CRP in general practice gave a rise in costs for the Health Service System, but also considerable savings for the laboratories, yielding a total savings of $111 160 per year for a Danish county with 340 000 inhabitants.

Selection bias.
The 29 clinics participating in the study were compared with the 12 clinics in the catchment area that declined participation. There were no significant differences for the number of requests for CRP from the laboratory, the use of ESR, the prescription of antibiotics, and the number and ages of the GPs affiliated with the clinics. The same parameters were compared for the 16 clinics with an inclusion rate >75% and the 13 clinics with a low inclusion rate, and no significant differences were found.


   Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
We have, under controlled and randomized conditions, given GPs access to quick CRP measurements and have used independent administrative registries to monitor changes in their behavior. This method is in contrast with previous published studies where GPs were asked if a CRP value had influenced their prescription of antibiotics or would have given them better clinical information compared with ESR (12)(13).

study validity
Some clinics had a low inclusion rate in the control period. This probably reflects difficulties in remembering to include patients in a routine situation. To ensure a high internal validity, we excluded all patients from clinics with a low inclusion rate. In the test for selection bias, participating clinics were found representative for all clinics in the catchment area.

esr
Some results in this study were found significant at the level of general practices as well as at the level of included patients. At the level of included patients, the use of ESR decreases from 46.3% for control patients to 35.3% for intervention patients (Table 2Up ). If we look at the total use of ESR by GPs and not only at ESR used for the patients included in this study, the decrease remains significant, at a total of 8% (Table 5Up ). This decrease was achieved after only 3 to 4 months of intervention, and the decrease will probably continue over a period of 4 to 5 years, as has been seen for clinical hospital departments introduced to CRP (21).

blood samples mailed to the laboratory
The number of blood samples forwarded from general practices to the laboratory decreased significantly both at the level of included patients and at the level of GPs. In a previous study, we found that CRP is requested in 34% of all blood samples mailed from general practices (10). In that study, it was not possible to detect whether CRP was requested as an additional test to other primarily ordered tests or whether CRP was actually the blood test necessitating the blood sample. The marked decrease in the number of forwarded blood samples found in this study indicates that CRP actually is a blood test that provokes a blood sample in general practice.

prescription of antibiotics
Surprisingly, we found no major changes in the prescription of antibiotics by GPs (Table 3Up ). From previous published studies, it could be hypothesized that the overall use of antibiotics would remain unaffected on the basis of more appropriate use of antibiotics, which means a decrease in prescriptions of antibiotics to patients with low CRP values and an increase in the number of prescriptions to patients with high CRP values. In this study, we found that exactly the same number of patients were prescribed an antibiotic at a certain magnitude of CRP values, regardless of whether the test results were given within minutes or days (Table 3Up ). This observation together with a same-day dispense rate of 70% for both periods (Table 4Up ) illustrates that the effect of the clinical use of the test seems to be uniform for both intervention and control periods. In control periods, antibiotics were prescribed and dispensed before the GP knew the CRP value. The test result, therefore, was not included in the diagnostic process, but perhaps was used as a kind of quality assurance for the clinical decision. It appeared that this pattern of application was copied during the intervention periods, although the test result should have been used as a part of the clinical decision-making process.

The group of patients with CRP values within the health-related reference interval but having an antibiotic prescribed had exactly the same distribution of infectious diseases as seen for the whole study population (Table 1Up ). This means that tentative diagnoses such as pneumonia, sore throat, and sinusitis were dominant and accounted for >60% of suspected infectious diseases (Table 1Up ). In general practice, the diagnostic value of CRP of these three diseases is well documented (5)(6)(8). For suspected bacterial pneumonia, the negative predictive value of a CRP value <50 mg/L is 95%, which means that only 1 of 20 patients will have bacterial pneumonia and a CRP value <50 mg/L simultaneously (5). The predictive value of a CRP value <10 mg/L would be even higher; however, 20% of patients with health-related CRP values had an antibiotic prescribed. The focus of this study was to investigate changes in the behavior of GPs who have CRP as a near-patient test, not to assess the ability of CRP to distinguish between bacterial and viral infection; therefore, we did not analyze culture data on every patient suspected for an infectious disease. The available literature supports the ability of CRP, although it is an nonspecific marker of infectious disease, to distinguish between bacterial and viral diseases (5)(6)(7)(8)(9)(10)(11)(12)(13). If we accept this ability to distinguish between diseases, we should have seen a decrease in the prescription of antibiotics to patients with low CRP values during the intervention periods and an increase in the prescription of antibiotics to patients with high CRP values, but this was not seen. Therefore, it seems reasonable to assume that implementation of clinical guidelines for the use of CRP in general practice could give a more appropriate use of antibiotics.

For a single subgroup of patients, a quick CRP result had an effect. Patients tentatively diagnosed clinically as having an infectious disease and with CRP values >50 mg/L collected their antibiotics sooner from pharmacies when the CRP measurement was made in the clinics (Table 4Up ). This suggests that the GPs encouraged their patients to collect their antibiotics the same day, because a high CRP value indicates not only a bacterial infection, but also the severity of the infection (4).

telephone consultations
At the level of included patients, a significant decrease in the number of telephone consultations during the follow-up periods during intervention was seen, probably reflecting that patients had received the test result at the primary consultation and that their case was then closed. It was not possible for us to evaluate this result at the level of GPs because we only had permission to receive data for follow-up consultations for included patients.

reasons for measuring crp
Regarding the reasons for CRP measurements, only small differences between the study periods were noticeable. For both periods, a major part of the tests was used for diagnosing a new disease; however, during intervention periods this use was significantly more frequent. This result reflects that the GPs found having the test result of the CRP test while the patient was still in the clinic more useful for diagnostic purposes. A decrease in the frequency of using CRP for follow-up purposes was revealed. CRP is known to be very useful for monitoring the treatment course of infectious patients, by using the patients as their own references (4). One could consider that a decrease in follow-up testing could give rise to several recurrences and, therefore, higher costs. We found that the decrease in follow-up testing was seen mainly for the group of patients with noninfectious disease, which typically means patients with chronic inflammatory diseases.

cost effectiveness
Implementation of a near-patient test for CRP in general practice in the county of Vejle would give the Health Service System a direct cost of $69 400 per year. The laboratories in the county would save $180 560 per year; because the counties are the owners of the hospitals in Denmark, the overall cost reduction would be $111 160 for the county of Vejle.

In conclusion, we have evaluated the clinical, organizational, and economic consequences of implementing a near-patient test for CRP in general practice. Although the clinical alterations were small but relevant, we still calculate a direct cost reduction of approximately $110 000 per year for a Danish county with 340 000 inhabitants. If implementation is followed by education and clinical guidelines, additional beneficial outcome effects seems possible, based on an additional reduction in the use of ESR and a more appropriate use of antibiotics.


   Acknowledgments
 
This study received financial support from the Danish Medical Research Council (grant no. 9602265), The Danish Health Insurance Fund (grant no. 11/024-96), The Danish Research Foundation for General Practice (grant no. FF-2-02-16), The Fund for Medical Research in Vejle County (grant no. 13/1995), The Quality Assurance Fund for general practice in Vejle County, and The Memorial Foundation for Johs. M. Klein and wife (J 664.14). Nycomed Pharma AS sponsored all near-patient tests, and their Danish division introduced GPs and their assistants to the test. We thank all participating GPs and their assistants. Jannie Kilsmark, Bodil Munk Hansen, and Frank Ingemann Jensen at the regional Health Service System office made it possible for us to use data from the health registries. At the Department of Clinical Chemistry, Vejle Hospital, EDP technologist Birgit J. Madsen extracted data from the Laboratory Information System and chief technologist Carsten Thomsen performed the economic assessment of laboratory services. Michael Væth, Department of Biostatistics, Aarhus University, Aarhus, Denmark, gave statistical advice while we were designing the study and while we were writing the final manuscript.


   Footnotes
 
1 Nonstandard abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell count; GP, general practitioner; and CI, confidence interval.


   References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 

  1. Pourcyrous M, Bada HS, Korones SB, Baselski V, Wong SP. Significance of serial C-reactive protein responses in neonatal infection and other disorders. Pediatrics 1993;92:431-435. [Abstract/Free Full Text]
  2. Hansson LO, Axelsson G, Linne T, Aurelius E, Lindquist L. Serum C-reactive protein in the differential diagnosis of acute meningitis. Scand J Infect Dis 1993;25:625-630. [ISI][Medline] [Order article via Infotrieve]
  3. Oosterhuis WP, Zwinderman AH, Teeuwen M, van Andel G, Oldenziel H, Kerkhoff JF, et al. C reactive protein in the diagnosis of acute appendicitis. Eur J Surg 1993;159:115-119. [ISI][Medline] [Order article via Infotrieve]
  4. Hansson LO, Lindquist L. C-reactive protein: its role in the diagnosis and follow-up of infectious diseases. Curr Opin Infect Dis 1997;10:196-201.
  5. Melbye H, Straume B, Aasebo U, Brox J. The diagnosis of adult pneumonia in general practice. The diagnostic value of history, physical examination and some blood tests. Scand J Prim Health Care 1988;6:111-117. [Medline] [Order article via Infotrieve]
  6. Hansen JG, Schmidt H, Rosborg J, Lund E. Predicting acute maxillary sinusitis in a general practice population. Br Med J 1995;311:233-236. [Abstract/Free Full Text]
  7. Hansson LO, Carlsson I, Hansson E, Hovelius B, Svensson P, Tryding N. Measurement of C-reactive protein and the erythrocyte sedimentation rate in general practice. Scand J Prim Health Care 1995;13:39-45. [ISI][Medline] [Order article via Infotrieve]
  8. Hjortdahl P, Melbye H. Does near-to-patient testing contribute to the diagnosis of streptococcal pharyngitis in adults?. Scand J Prim Health Care 1994;12:70-76. [Medline] [Order article via Infotrieve]
  9. Lindbäck S, Hellgren U, Julander I, Hansson LO. The value of C-reactive protein as a marker of bacterial infection in patients with septicaemia/endocarditis and influenza. Scand J Infect Dis 1989;21:543-549. [ISI][Medline] [Order article via Infotrieve]
  10. Dahler-Eriksen BS, Lassen JF, Lund ED, Lauritzen T, Brandslund I. C-reactive protein in general practice—how commonly is it used and why. Scand J Prim Health Care 1997;15:35-38. [ISI][Medline] [Order article via Infotrieve]
  11. Dahler-Eriksen BS, Lassen JF, Petersen PH, Lund ED, Lauritzen T, Brandslund I. Evaluation of a near-patient test for C-reactive protein used in daily routine in primary healthcare by use of difference plots. Clin Chem 1997;43:2064-2075. [Abstract/Free Full Text]
  12. Hjortdahl P, Landaas S, Urdal P, Steinbakk M, Fuglerud P, Nygaard B. C-reactive protein: a new rapid assay for managing infectious disease in primary health care. Scand J Prim Health Care 1991;9:3-10. [Medline] [Order article via Infotrieve]
  13. Lindbæk M, Hjortdahl P. C-reaktivt protein i allmenpraksis. Et viktig diagnostisk hjelpemiddel ved infeksjoner. [C-reactive protein in primary care—a useful diagnostic tool in infections. In Norwegian; English summary]. Tidsskr Nor Lægeforen 1998;118:1176-1179. [Medline] [Order article via Infotrieve]
  14. Sandberg S. Near patient testing must improve patient care [Editorial]. Scand J Prim Health Care 1994;12:65-67. [Medline] [Order article via Infotrieve]
  15. Rainey PM. Outcomes assessment for point-for-care testing [Editorial]. Clin Chem 1998;44:1595-1596. [Free Full Text]
  16. Hobbs R. Near patient testing in primary care [Editorial]. Br Med J 1996;312:263-264. [Free Full Text]
  17. Olesen F, Mainz J, Lassen JF. Research, technology assessment, and quality assurance. Eur J Gen Pract 1997;2:162-165.
  18. Sørensen HT, Schulze S. Danish health registries [Editorial]. Dan Med Bull 1996;43:463.[ISI][Medline] [Order article via Infotrieve]
  19. Sørensen HT, Steffensen FH, Schønheyder HC, Grøn P, Sabroe S. Use of microbiological diagnostics and antibiotics in Danish general practice. Int J Technol Assess Health Care 1996;12:745-751. [ISI][Medline] [Order article via Infotrieve]
  20. Armitage P, Berry G. Statistical method in medical research, 3rd ed. Oxford: Blackwell Science Ltd, 1995:620 pp..
  21. Dahler-Eriksen BS, Lassen JF, Lauritzen T, Lund ED, Brandslund I. Forskelle i brugen af C-reaktivt protein og sænkningsreaktion i almen praksis og på sygehus. Udvikling fra 1986 til 1995. [Differences in the quantitative use of C-reactive protein and erythrocyte sedimentation rate between general practice and hospital. A register-based study from 1986 to 1995. In Danish; English summary]. Ugeskr Læger 1998;160:4868-4872. [Medline] [Order article via Infotrieve]
  22. Bland M. An introduction to medical statistics. Oxford: Oxford University Press, 1995:396 pp..



The following articles in journals at HighWire Press have cited this article:


Home page
J Antimicrob ChemotherHome page
M. Cizman, T. Srovin, M. Pokorn, S. Cad Pecar, and S. Battelino
Analysis of the causes and consequences of decreased antibiotic consumption over the last 5 years in Slovenia
J. Antimicrob. Chemother., May 1, 2005; 55(5): 758 - 763.
[Abstract] [Full Text] [PDF]


Home page
Clin TrialsHome page
S. M Eldridge, D. Ashby, and G. S Feder
Informed patient consent to participation in cluster randomized trials: an empirical exploration of trials in primary care
Clinical Trials, April 1, 2005; 2(2): 91 - 98.
[Abstract] [PDF]


Home page
BMJHome page
C. P Price
Regular review: Point of care testing
BMJ, May 26, 2001; 322(7297): 1285 - 1288.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dahler-Eriksen, B. S.
Right arrow Articles by Brandslund, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dahler-Eriksen, B. S.
Right arrow Articles by Brandslund, I.
Related Collections
Right arrow Clinical Immunology
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS